Rystiggo Market Report 2026

Rystiggo Market Overview

• The Rystiggo market growth in the historic period has been driven by improved understanding of autoimmune disease mechanisms, increasing diagnosis rates of gMG • Market expansion is supported by increasing investments in autoimmune biologics, rising demand for disease-modifying therapies • Growth Driver: Impact Of Rising Myasthenia Gravis Prevalence On The Growth Of The Market • Market Trend: Advancements In Treatments For Generalized Myasthenia Gravis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rystiggo Market?

Rystiggo refers to rozanolixizumab-noli, a medication used for treating generalized myasthenia gravis (gMG) in adults. It is a subcutaneous infusion treatment that works by targeting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG autoantibodies, which are implicated in the condition. The main types of rystiggo include monotherapy and combination therapy. Monotherapy refers to the treatment of a disease or condition using a single drug or therapeutic agent. In medical practice, it means using only one medication, rather than a combination of drugs, to manage a patient's condition. The various clinical indications include generalized myasthenia gravis (GMG) and autoimmune neurological disorders (off-label use) and are distributed through several channels, such as hospitals and clinics and diagnostic centers.

What Is The Rystiggo Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in autoimmune biologics, rising demand for disease-modifying therapies, expansion of precision immunology research, growing adoption of home-based infusion models, advancement of next-generation antibody platforms. Major trends in the forecast period include increasing adoption of fcrn inhibitor therapies, rising demand for targeted autoimmune treatments, growing preference for subcutaneous biologic delivery, expansion of precision neurology therapeutics, enhanced focus on patient-centric treatment regimens.

Global Rystiggo Market Segmentation

1) By Type: Monotherapy, Combination Therapy 2) By Clinical Indication: Generalized Myasthenia Gravis (gMG), Autoimmune Neurological Disorders (Off-Label Use) 3) By Distribution Channel: Hospitals And Clinics, Diagnostic Centers

What Are The Drivers Of The Rystiggo Market?

The increasing prevalence of myasthenia gravis is anticipated to drive the growth of the rystiggo market in the future. Myasthenia gravis (MG) is a chronic autoimmune disorder that affects the neuromuscular system, causing weakness in the skeletal muscles. The rising prevalence of Myasthenia Gravis is due to improved diagnosis, an aging population, increased awareness, better reporting systems, and longer life expectancy among those affected. Rystiggo (rozanolixizumab) is a monoclonal antibody used to treat myasthenia gravis (MG) by targeting and inhibiting the action of the neonatal Fc receptor (FcRn). For instance, in February 2024, according to the National Institutes of Health, a US-based government agency, in 2021, around 82,715 adults in the United States were living with myasthenia gravis (MG), resulting in an estimated prevalence of 320.2 cases per million people. Therefore, the rising prevalence of myasthenia gravis is driving the growth of the rystiggo industry. Rising healthcare expenditure is expected to fuel the growth of the rystiggo market in the coming years. Healthcare expenditure refers to the overall spending on medical services, products, and public health initiatives aimed at improving and maintaining health. The increase in healthcare expenditure is driven by an aging population requiring more medical care and the growing prevalence of chronic diseases such as diabetes and heart conditions. Healthcare expenditure for rystiggo covers medication costs, infusion services, monitoring, specialty pharmacies, and patient support programs for managing generalized myasthenia gravis. For instance, in November 2024, the Health Foundation, a UK-based independent charity, reported that the Department of Health and Social Care's planned daily spending is projected to increase from around $219.5 billion (£177.9 billion) to $239.3 billion (£190.1 billion) in 2024/25, and further to $254.5 billion (£200.5 billion) in 2025/26. Therefore, the growing healthcare expenditure is driving the expansion of the rystiggo industry.

Key Players In The Global Rystiggo Market

Major companies operating in the rystiggo market are UCB Inc.

Global Rystiggo Market Trends and Insights

The key trend in the rystiggo market is developing innovative products, such as new treatments of generalized myasthenia gravis, to address unmet medical needs, improve patient outcomes, and gain a competitive edge in the healthcare market. Treatment for generalized myasthenia gravis involves symptom management with acetylcholinesterase inhibitors, immunosuppressive therapies, targeted biological agents, and interventions like plasma exchange or thymectomy to reduce autoantibody activity and improve muscle strength. For instance, in June 2023, UCB Inc., a Belgium-based pharma company, received FDA approval for RYSTIGGO (rozanolixizumab-noli), marking it as the first treatment specifically targeting adults with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. The approval follows promising results from the Phase 3 MycarinG study, which demonstrated significant improvements in daily functioning for patients. RYSTIGGO is administered via subcutaneous infusion once a week for six weeks. The approval has been positively received by patient advocacy groups, emphasizing its potential to meet unmet medical needs in the gMG community.

Regional Insights

North America was the largest region in the rystiggo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rystiggo Market?

The rystiggo market consists of sales of products including efgartigimod alfa-fcab (Vyvgart), zilucoplan (Zilbrysq), and eculizumab (Soliris). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rystiggo Market Report 2026?

The rystiggo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rystiggo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.